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Abstract
Background: Vertebral Fracture Assessment (VFA) is a useful tool to detect the vertebral fracture (VF) with low cost
and radiation exposure. We aimed to compare screening strategies including VFA and spine radiography (X-ray) for
detecting VF in terms of clinical effectiveness, cost and radiation exposure.
Methods: Three screening strategies: 1) X-ray following VFA, 2) VFA only, and 3) X-ray only were compared using a
Markov model based on administrative data from South Korea in a population aged ≥50 years. We compared the
incidence of new VFs, cost-effectiveness of reducing new VFs and radiation exposure in each strategy.
Results: The incidence of new VFs was reduced in all screening strategies compared to no screening: 29.4% for
women and 12.5% for men in both X-ray following the VFA and VFA only strategies and 35% for women and 17.
5% for men in the X-ray only strategy. The X-ray following VFA strategy had the lowest cost, followed by the X-ray
only, and VFA only strategies. The radiation doses for X-ray only were 2,647–2,989 μSv and 3,253–3,398 μSv higher
than in the X-ray following VFA and VFA only strategies. The new VF prevention effect was greater in women, and
more prominent in older people (women ≥ 70, men ≥ 80) than people ≥ 50 years.
Conclusions: The X-ray following VFA strategy is a cost-effective option for screening prevalent VF to prevent new
VF in people aged ≥50 years due to its high effectiveness, lowest cost, and least radiation exposure.
Keywords: Spinal fracture, Radiography, Diagnostic imaging, Cost effectiveness, Radiation
Background
Vertebral fracture (VF) is the most common sign of osteo-
porosis and indicates a higher risk of subsequent VFs [1, 2].
According to previous literature, only around one-fourth to
one-third of prevalent VFs are recognized clinically [3–5].
However, detection of prevalent VFs is important because
new VFs can be prevented by starting osteoporosis medica-
tion at the time of detection, even though bone mineral
density (BMD) is not low [5–8]. In clinical practice, screen-
ing of VFs is rarely performed because of its cost, fear about
radiation exposure, and inconvenience.
Spine radiography (X-ray) and vertebral fracture assess-
ment (VFA) by dual energy X-ray absorptiometry (DXA)
can readily detect prevalent VFs [9]. Until now, lateral
thoracic and lumbar X-rays have been used as the gold
standard for VF identification [6], because of the potential
false negative rate of VF due to the poor image quality of
the upper thoracic vertebrae in VFA [10, 11]. However,
VFA has recently been considered as a practical and reli-
able diagnostic tool with a lower radiation dose of
2–50 μSv compared to 600 μSv for X-rays [12] and
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provides greater convenience in assessing VFs at the same
time as measurement of BMD [5].
Increasing evidence indicates that the sensitivity and spe-
cificity of VFA are as high as those of X-ray with lower cost
and radiation exposure [13]. There has been one study of
the cost-effectiveness of VFA versus X-ray in postmeno-
pausal women with osteopenia [14] but none assessing the
clinical benefits and disadvantages of X-ray and VFA as a
screening tool in the general population. Therefore, in this
study, we aimed to compare the clinical effectiveness, cost-
effectiveness, and radiation exposures of VF screening
strategies in adults aged 50 years and older using X-ray fol-
lowing VFA, VFA only and X-ray only as performed to
detect prevalent VFs early and to prevent new VFs.
Methods
Model overview
A model structure comparing the screening strategies
for prevalent VFs was developed from a review of the
literature [15], clinical guidelines [9, 16], and expert
opinion. A Markov model using a cohort simulation
with each cohort of 1000 samples for women and men
aged 50 years and older that compared screening strat-
egies for identifying the presence of both asymptomatic
and symptomatic VFs was created. We ran three Markov
models simultaneously, one for each of the screening
strategies for detecting prevalent VFs: 1) X-ray following
VFA, which is screening of VFA followed by X-ray as
confirmation test in patients who were suspicious of
vertebral fracture, 2) VFA only, and 3) X-ray only. This
index strategy of screening was compared to not doing
any screening strategy before recognition of a new VF
(No screening) (Fig. 1a).
The health states used in the Markov model were No
VF, Prevalent VF, Post VF, New VF, and VFA impossible.
Prevalent VF included radiographic VFs diagnosed by
X-ray as well as symptomatic VFs. The subjects started
at an initial state of No VF or Prevalent VF. We assumed
that the patients with a VF could not move back to the
No VF state. All patientswho tested positive for VF were
assumed to receive anti-osteoporotic therapy for one
year, and patients who tested negative for VF were
a
b
Fig. 1 Model structure for screening strategies to identify prevalent VF. T, test; VF, vertebral fracture; VFA, vertebral fracture assessment; (+), positive; (−),
negative. a Simplified decision tree: Subjects who tested positive for prevalent VF were treated with anti-osteoporotic drugs, and the cycle length of
the screening test was two years. b State transition diagram: the Markov model had five health states: No VF, Prevalent VF, Post VF, New VF, and VFA
impossible. If the diagnosis of the new VF has been made once, patients with drug therapy are ruled out of the simulation targets
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assumed not to receive anti-osteoporotic therapy. They
could either remain in the present state or transit to Post
VF or New VF in a subsequent cycle depending on the
effect of drug therapy. Throughout the 10-year period,
each subject was allowed to experience a new VF after
the first VF. Once diagnosis of a new VF was made, a
patient on drug therapy was excluded from the simula-
tion. The model also considered VFA impossible as the
absorbing state, which means that the VFA was unread-
able as a result of poor image quality (Fig. 1b) [11].
Probability data and key assumptions
The prevalence of VFs in adults aged 50 years and older
was obtained from a large-scale cohort study conducted
in South Korea [17, 18]. The incidence of VFs was esti-
mated based on the linked data between a hospital co-
hort and the National Health Insurance (NHI) claims
database of South Korea [19]. Moreover, the adjusted
value was multiplied by an asymptomatic to symptom-
atic VF ratio of 2.8, which was the weighted average cal-
culated by the literature [4, 20, 21]. This was used
because the incidence of VFs before adjustment only
considers patients who are clinically diagnosed VFs
(Table 1).
In regard to diagnostic accuracy of VFA, the sensitivity
and specificity VFA per-patient were taken from a pub-
lished systematic review and report [13, 22]. In addition,
we calculated the unreadable vertebrae on the VFA as
0.03 (95% CI, 0.04–0.17) per patient and 0.05 (95% CI,
0.04–0.08) per vertebra using random-effect estimates
[22]. We assumed that the X-ray has a sensitivity and
specificity of 1.00 as the gold standard (Table 1).
The relative risk (RR) for new VFs was derived from
five systematic review studies [19, 23–26]. The pooled
RR was calculated by averaging the RRs weighted by the
market share of the prescribed drug based on the 2012
claims database by health insurance review and assess-
ment service (HIRA) (Table 1). We assumed that
patients with diagnosed VFs will receive pharmacother-
apy for a one year treatment period according to a previ-
ous trial [7] and expert opinions. However, the model
did not consider the likelihood of adverse drug reaction
Table 1 Summary of the input parameters in the model for base case analysis and univariate sensitivity analysis
Parameter Valuea Sources Note
Women Men
Probabilities
VF prevalence 0.22 [0.08] 0.11 [0.03] HIRA, [17, 18] NHI database [Community-based cohort]
two-year VF incidence 0.12 [0.13] 0.05 [0.05] HIRA, [32] NHI database [Community-based cohort]
two-year new VF incidence 0.22 [0.23] 0.22 [0.23] [19, 32] Hospital cohort- NHI database linked data [Community-based cohort]
RR of new VF on drug therapy 0.58 [0.64] 0.38 [0.41] [19, 23–26] Meta-analysis literature review, pooled RR [decrease by 10%]
Diagnostic accuracy
Sensitivity of X-ray 1.00 1.00 Gold standard
Specificity of X-ray 1.00 1.00 Gold standard
Sensitivity of VFA 0.82 [0.74] 0.82 [0.74] [22] SR [95% CI lower limit, conservative]
Specificity of VFA 0.93 [0.89] 0.93 [0.89] [22] SR [95% CI lower limit, conservative]
VFA impossible 0.03 [0.05] 0.03 [0.05] [22] SR, per patient [per vertebrae]
Costs (€)b
VFAc 17 [40] 17 [40] [27] 50% of X-ray test costs [Increase by 200% of X-ray costs, conservative]
X-rayc 24 [17] 24 [17] HIRA EDI code, thoracic and lumbar spine in the AP and lateral
VFs treatment 1526 [1249] 1707 [1336] HIRA NHI database, per patient [Mild VF relatively]
Physician visits 9 9 HIRA NHI database, per visit
Drug therapy 180 194 HIRA Drug weighted average charge, one-year administration
Procedure 809 934 HIRA NHI database, only in symptomatic VF cases
Radiation doses (μSv)
X-ray 600 600 [12]
VFA 25 [2] 25 [2] [12] Average level of 2 to 50 μSv [lower limit]
VF vertebral fracture, HIRA Health Insurance Review and Assessment Service, NHI National Health Insurance, RR relative risk, AP anterior-posterior, VFA vertebral
fracture assessment, SR systematic review
aValue in brackets, []: Inputs data for univariate sensitivity analysis
bKorean won converted to euros (€) using an exchange rate of 1€ = 1482 KRW (2013)
cVFA and X-ray costs included the test and a physician visit
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from unnecessary treatment with a false-positive VFA
image.
Cost and radiation exposure data
Cost data were collected from the NHI claims data from
the HIRA in South Korea [22]. The unit costs for two cat-
egories, screening tests and VF treatment, are presented
in Table 1. When estimating the costs of the index tests,
X-ray was defined as using standard radiographic tech-
niques for VF identification [6]. Since we do not have de-
termined cost of VFA, we calculated that VFA imaging
would cost half that of the X-ray, reflecting the U.S. rela-
tive cost [27]. The treatment cost of VFs included medical
costs such as physician visits, drug therapy, or related pro-
cedures. A discount rate of 5% was applied to the future
costs with half-cycle corrections according to the South
Korean economic evaluation guidelines [28]. All costs
were estimated in year 2013 euros using the health care
component of the Consumer Price Index [29] and the ex-
change rate (1€ = 1482 KRW in 2013).
We applied the exposure to radiation at every cycle
length of the test at 600 μSv for X-ray; 25 μSv─ middle
level of the reported range (2–50 μSv)─for VFA; and
625 μSv for X-ray following VFA, respectively [12]. The
strategy of no screening was assumed to have no signifi-
cant exposure to radiation.
Statistical analysis
In the base case analysis, we compared the clinical bene-
fits and harm of doing the screening strategies (defined
as Do screening, which presents the average expected
values of the X-ray following VFA, VFA only, and X-ray
only strategies) every two years and No screening. The
outcome measures included incidence of new VFs (%),
costs of tests and VFs treatment (€), and radiation ex-
posure (μSv) of the three screening strategies compared
to the No screening strategy. Consequently, the results
were calculated as follows.
Incremental effectiveness ΔEð Þ
¼ Effectindex test–Effectno screening %ð Þ
Incremental costs ΔCð Þ
¼ Costsindex test–Costsno screening €ð Þ
Incremental radiation exposure ΔREð Þ
¼ Radiation dosesindex test–Radiation dosesno screening μSvð Þ
* Index test: X-ray following VFA, VFA only, and X-ray
only as the Do screening.
Next, we performed univariate and multivariate sensi-
tivity analyses to probe the validity of our model. In the
univariate sensitivity analyses, the parameters of the
prevalence and incidence of VFs, efficacy of drugs, diag-
nostic accuracy of VFA, costs of test and VFs treatment,
and radiation doses of VFA were varied, using the vari-
ous sources, range, and conservative approach (Table 1).
Since there was no recommended test interval available
in the guidelines [16], multivariate sensitivity analysis
was conducted using a cycle length of one year.
Finally, the subgroup analysis of old age was con-
ducted for women aged 70 years and older and all men
aged 80 years and older since these age groups are rec-
ommended especially for VFA in the guidelines [16, 30],
for which the input parameters are presented in Table 2.
All the statistical analyses were performed by SAS soft-
ware version 9.2 (SAS Institute Inc., Cary, NC, USA).
Table 2 Summary of the input parameters in the model for multivariate sensitivity analysis and subgroup analysis
Parameters Valuea Sources Note
Women Men
Cycle length one-year
one-year VF incidence 0.06 0.02 HIRA NHI database
one-year new VF incidence 0.11 0.11 [19] Hospital cohort-NHI database linked data
VFs treatment costa (€) 1458 1509 HIRA NHI database
Women aged 70 and older, men aged 80 and older
VF prevalence 0.43 0.46 [18] Community-based cohort
two-year VF incidence 0.29 0.17 HIRA NHI database
two-year new VF incidence 0.32 0.32 [19] Hospital cohort-NHI database linked data
RR of new VF on drug therapy 0.60 0.60 [33] Meta-analysis, pooled RR
Sensitivity of VFA 0.88 0.88 [34] Diagnostic accuracy study for elderly adults
Specificity of VFA 0.99 0.99 [34] Diagnostic accuracy study for elderly adults
VFs treatment costa (€) 1513 1675 HIRA NHI database
HIRA Health Insurance Review and Assessment Service, NHI National Health Insurance, VF vertebral fracture, VFA vertebral fracture assessment, RR relative risk
aKorean won converted to euros (€) using an exchange rate of 1€ = 1482 KRW (2013)
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The model was estimated using TreeAge Pro 2013
(TreeAge Software, Williamstown, MA).
Results
Base case analysis
No screening versus do screening for prevalent VF
For women aged 50 and over for a 10-year time horizon,
the new VF incidence was 54.6% for No screening, and
23.3% for Do screening with a two-year interval
(calculated as the average incidence of X-ray following
VFA, VFA only, and X-ray only strategies: 25.2%, 25.2%,
and 19.6%, respectively). The expected costs were €967
higher for Do screening; and the radiation exposure was
1427 μSv per capita for Do screening. For men aged 50
and over it was also associated with lower new VF inci-
dence (8.4% for Do screening vs. 22.5% for No screening)
and higher costs (€658 for Do screening vs. €27 for No
screening). Comparing Do screening to identify a preva-
lent VF to No screening, the new VF incidence decreased
by 23.3% with increased costs of €810, and radiation
exposure of 1422 μSv for both women and men aged 50
and over as the weighted average by the 2013 registration
population by gender based on the South Korean
Statistical Information Service statistics (Table 3) [29].
Three screening strategies for prevalent VF
Among the three screening strategies performed every
two years (Table 3), the X-ray following VFA and VFA
only strategies showed the same clinical effect of redu-
cing the new VF incidence by as much as 29.4% for
women, and 12.5% for men. The most effective strategy
was the X-ray only strategy with a new VF incidence
reduction of 35% for women and 17.5% for men over a
10-year period. With regard to the costs, X-ray following
VFA strategy was less expensive than the others for both
women and men. The second economic option was
X-ray only strategy, then VFA only strategy (ΔC of €821,
€938, and €1142 for women; €477, €515, and €899 for
Table 3 Results of the base case analysis and multivariate sensitivity analysis for the diagnostic strategies during a 10-year period
Category Diagnostic strategies Effectiveness (%) ΔEa (%) Costs (€) ΔCb (€) ΔREc (μSv)
Women
Base case No screening 54.6 60
Do screeninge 23.3 −31.3 1027 967 1427
X-ray following VFA 25.2 −29.4 881 821 747
VFA 25.2 −29.4 1202 1142 141
X-ray 19.6 −35.0 998 938 3394
Multivariate sensitivity (Cl = 1 year) No screening 54.6 60
Do screeninge 23.2 −31.4 1102 1042 2455
X-ray following VFA 24.8 −29.7 862 802 996
VFA 24.8 −29.7 1418 1358 254
X-ray 19.9 −34.7 1025 966 6115
Men
Base case No screening 22.5 27
Do screeninge 8.4 −14.2 658 630 1416
X-ray following VFA 10.1 −12.5 504 477 556
VFA 10.1 −12.5 927 899 147
X-ray 5.0 −17.5 542 515 3545
Multivariate sensitivity (Cl = 1 year) No screening 54.6 60
Do screeninge 8.3 −14.2 734 707 2526
X-ray following VFA 10.1 −12.4 498 471 828
VFA 10.1 −12.4 1143 1116 267
X-ray 4.8 −17.7 560 533 6483
Totald Do screeninge 16.4 −23.3 854 810 1422
VFA vertebral fracture assessment, Cl Cycle length
aΔE (Incremental effectiveness, %) = Effectindex test–Effectno screening in new VFs incident
bΔC (Incremental Costs, €) = Costsindex test–Costsno screening in the costs of test and VFs treatment
cΔRE (Incremental radiation exposure, μSv) = Radiation dosesindex test–Radiation dosesno screening; Radiation dosesno screening was assumed to be ‘0 μSv’
dIn the base case, the weighted average by the registration population by gender (female = 8,649,974 people; male = 7,590,057 people) based on Statistics
eDo screening presents the average expected values of X-ray following VFA, VFA only, and X-ray only
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men per capita, respectively). Also, the 10-year radiation
doses in the X-ray only strategy was from 2647 to
2989 μSv and 3253 to 3398 μSv higher than in the X-ray
following VFA or VFA only strategies for both women
and men.
Sensitivity analysis
The results of the univariate sensitivity analysis com-
pared with the base case analysis are shown in Fig. 2.
The input parameters of the sensitivity analysis are given
in Table 1. The decrease of VF prevalence indicates that
not only was the new VF incidence lower, by 1.7% to
6.9%, but the expected cost was reduced by €70 to €112
in all the screening strategies for both women and men.
A similar pattern was found for VF incidence, as
reduced effectiveness and cost resulted from an increase
in VF incidence. Even though these parameters made
great changes in effectiveness and cost, the relative rank-
ings among the strategies did not change. In addition,
when the sensitivity and specificity of VFA were reduced,
the costs of the strategies that included VFA changed.
However, the relative rankings of the strategies were
maintained.
The multivariate sensitivity analysis examined the
influence of a one-year cycle length compared to the
base case analysis of a cycle length of two years during a
10-year period (Table 3). In particular, the X-ray follow-
ing VFA strategy performed every year for women was
beneficial as it was associated with an effect increase in
terms of new VF incidence reduction, cost savings, and a
slight increase in radiation dose, whereas the X-ray only
produced the opposite effect of the X-ray following VFA
strategy. The results of the X-ray following VFA strategy
for men were similar regardless of the cycle length and
the X-ray only strategy of every year increased the
effectiveness, cost, and radiation dose. On average, the
effectiveness of Do screening on the reduction of new
VF incidence was almost identical between the one- and
two -year screen intervals. However, the expected cost
(about €80 in women and men) and the radiation expos-
ure (about 1000–1100 μSv in women and men) were
slightly increased in the one-year cycle length.
Fig. 2 VF, vertebral fracture; VFA, vertebral fracture assessment; RR, relative risk; (+), increase; (-), decrease (refer to Table 1). Effect and impact of
parameter variation on new VF incidence compared with the base case analysis; Costs and impact of parameter variation on costs compared
with the base case analysis. (a) represent for women and (b) for men
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Subgroup analysis
Figure 3 shows the results from the subgroup analysis for
old age people; women aged 70 and older and men aged
80 and older. The preventive effect of Do screening on
new VFs was 41.0% for women and 32.8% for men
compared with No screening. The expected costs were
€1602 per woman aged 70 and over, and €1429 per man
aged 80 and over. The radiation exposure for the old age
women and men was comparable with the base case
results. Among the three strategies, the overall expected
cost of X-ray only strategy was the highest in the subgroup
for old people whereas the cost of VFA only strategy was
the highest in the base case analysis (Data not shown).
Discussion
This study demonstrated that doing screening strategies
for prevalent VFs has a high preventive effect on
reducing new VF incidence for women and men aged
50 years and older compared to a No screening strategy.
A cost-effective option was X-ray following VFA strat-
egy, considering that the radiation exposure in X-ray
only strategy was much higher than the X-ray following
VFA or VFA only strategies.
For a change of two years into the one-year screening
interval, the average effects of the three screening strat-
egies for prevalent VF on reducing new VF incidence were
almost identical, but the X-ray following VFA strategy for
women was especially beneficial resulting in a reduction
of the incidence of new VFs, cost savings, and relatively
low levels of radiation dose. On average, the clinical effect
of incident VF reduction was more than two times in
women than in men, more in old people aged 70 and over
than in people aged 50 and over, and its effect on old
people was increased more in men than in women.
In clinical practice, the X-ray, the gold standard tool
for detecting VF, is not routinely performed in the clin-
ical evaluation of people at risk of future fractures. In
our study, considering the highest radiation exposure
and the second highest cost, a routine X-ray screening
strategy might be inferior to the X-ray following VFA.
Given that the worldwide average effective dose from
natural background radiation was reported to be
2.4 mSv per year [12], the potential risk to an individual
might be small because the annual radiation doses of the
X-ray strategy in our study had a much lower dose at
0.35 mSv. However, cyclical use could have a psycho-
logical impact on the compliance of people who are
eligible for routine screening for VF.
On the other hand, VFA had the lowest radiation dose
and a high preventive effect of new VFs. However, we
should carefully consider whether to replace the X-ray
with VFA because performing the VFA has a risk of mis-
diagnosis caused by false negative rates of about 20%
[10]; the costs of VFA are increased with the additional
costs of patients receiving unnecessary treatment with a
false-positive result. Moreover, even if most osteoporotic
VFs occur between T7 and L3, the poor image quality of
the upper thoracic vertebrae superior to T7 is a major
Fig. 3 Subgroup analysis by old age people who had received prevalent VF screening strategies compared to No screening in a 10-year time horizon. ΔE,
new VFs incident reduction; ΔC, increased costs; ΔRE, radiation exposure. VF, vertebral fracture; VFA, vertebral fracture assessment. a and b represent the
average values of the X-ray following VFA, VFA, and X-ray as a Do screening strategy
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limitation of VFA [11]. Thus our model applied the
unreadable probability of VFA, and additional confirma-
tory imaging (e.g. X-ray) should be considered.
The X-ray following VFA strategy can overcome these
problems of VFA with the lowest cost, lower radiation
dose than X-ray, and high effect of reducing the new VF.
In addition, it can assess VFs at the same time as BMD
assessment in contrast to X-ray, which may need referral
to another facility [8].
Our study has some limitations. First, since there were
no reliable data about adherence to screening and osteo-
porosis medication, we assumed 100% adherence for
screening as well as medication use. Therefore, this as-
sumption probably overstates the clinical effectiveness of
this study. In addition, the use of anti-osteoporotic agents
based on BMD values was not considered, since it would
be equally applicable to all the patients. Modeling that in-
cluded information on BMD values in the subject popula-
tion would be very complex, but it would be possible to
perform such additional modeling if real world data from
observational studies were included. Second, as we as-
sume that the costs of the VFA test would be half of the
X-ray as in the U.S., it should be updated for costs after
pricing in each countries. Third, our analysis did not con-
sider patient outcome or health-related quality of life
(HRQoL). However, this study has great strength that it
revealed the benefits and harm of X-ray following VFA,
VFA only, and X- ray only strategies, as a population
screening tool. Moreover, we used accurate data on preva-
lence, incidence and cost using real world data from the
NHI claims database to obtain a more accurate result. Al-
though the new DXA devices such as iDXA are not widely
used in the clinical field, the results of this study would be
different if we used such a device because of its high sensi-
tivity and specificity [31].
Conclusion
We suggest that routine screening for VF every one to two
years is justified in all populations aged 50 years and older.
In particular, an X-ray following VFA strategy can be a rele-
vant option for prevalent VF detection and new VF preven-
tion. Further studies of both HRQoL and cost-utility
analysis are needed to promote informed decision making.
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